Passive immunotherapy for anthrax toxin mediated by an adenovirus expressing an anti-protective antigen single-chain antibody

Kazuhiko Kasuya, Julie L. Boyer, Yadi Tan, D. Olivier Alipui, Neil R. Hackett, Ronald Crystal

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

In the 2001 U.S. bioterror attacks, 33,000 individuals required postexposure prophylaxis, 18 subjects contracted anthrax (11 inhalation, 7 cutaneous), and despite optimal medical therapy, 5 deaths resulted. Rapid protection against anthrax is required in a bioterrorism scenario; this study describes an in vivo gene transfer-based therapy that uses a human adenovirus (Ad)-based vector (AdαPAscAb) encoding a single-chain antibody directed against protective antigen (PA), a critical component of Bacillus anthracis lethal toxin. Following AdαPAscAb administration to mice, anti-PA single-chain antibody and anti-PA neutralizing activity were detected in serum over a 2-week period. Substantial survival advantage from anthrax lethal toxin was conferred by AdαPAscAb following administration from 1 to 14 days prior to toxin challenge, compared to no survival associated with an Ad vector expressing a control single-chain antibody. Passive immunotherapy with an Ad-based vector may be a rapid, convenient approach for protecting a susceptible population against anthrax, including use as an adjunct to antibiotic therapy.

Original languageEnglish
Pages (from-to)237-244
Number of pages8
JournalMolecular Therapy
Volume11
Issue number2
DOIs
Publication statusPublished - 1 Feb 2005
Externally publishedYes

Fingerprint

Single-Chain Antibodies
Passive Immunization
Adenoviridae
Anthrax
Antigens
Bioterrorism
Human Adenoviruses
Therapeutics
Anti-Bacterial Agents
Skin
Serum
Population
Genes
anthrax toxin

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this

Passive immunotherapy for anthrax toxin mediated by an adenovirus expressing an anti-protective antigen single-chain antibody. / Kasuya, Kazuhiko; Boyer, Julie L.; Tan, Yadi; Alipui, D. Olivier; Hackett, Neil R.; Crystal, Ronald.

In: Molecular Therapy, Vol. 11, No. 2, 01.02.2005, p. 237-244.

Research output: Contribution to journalArticle

Kasuya, Kazuhiko ; Boyer, Julie L. ; Tan, Yadi ; Alipui, D. Olivier ; Hackett, Neil R. ; Crystal, Ronald. / Passive immunotherapy for anthrax toxin mediated by an adenovirus expressing an anti-protective antigen single-chain antibody. In: Molecular Therapy. 2005 ; Vol. 11, No. 2. pp. 237-244.
@article{82560d68b85b4198add64b17765e8770,
title = "Passive immunotherapy for anthrax toxin mediated by an adenovirus expressing an anti-protective antigen single-chain antibody",
abstract = "In the 2001 U.S. bioterror attacks, 33,000 individuals required postexposure prophylaxis, 18 subjects contracted anthrax (11 inhalation, 7 cutaneous), and despite optimal medical therapy, 5 deaths resulted. Rapid protection against anthrax is required in a bioterrorism scenario; this study describes an in vivo gene transfer-based therapy that uses a human adenovirus (Ad)-based vector (AdαPAscAb) encoding a single-chain antibody directed against protective antigen (PA), a critical component of Bacillus anthracis lethal toxin. Following AdαPAscAb administration to mice, anti-PA single-chain antibody and anti-PA neutralizing activity were detected in serum over a 2-week period. Substantial survival advantage from anthrax lethal toxin was conferred by AdαPAscAb following administration from 1 to 14 days prior to toxin challenge, compared to no survival associated with an Ad vector expressing a control single-chain antibody. Passive immunotherapy with an Ad-based vector may be a rapid, convenient approach for protecting a susceptible population against anthrax, including use as an adjunct to antibiotic therapy.",
author = "Kazuhiko Kasuya and Boyer, {Julie L.} and Yadi Tan and Alipui, {D. Olivier} and Hackett, {Neil R.} and Ronald Crystal",
year = "2005",
month = "2",
day = "1",
doi = "10.1016/j.ymthe.2004.10.018",
language = "English",
volume = "11",
pages = "237--244",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Passive immunotherapy for anthrax toxin mediated by an adenovirus expressing an anti-protective antigen single-chain antibody

AU - Kasuya, Kazuhiko

AU - Boyer, Julie L.

AU - Tan, Yadi

AU - Alipui, D. Olivier

AU - Hackett, Neil R.

AU - Crystal, Ronald

PY - 2005/2/1

Y1 - 2005/2/1

N2 - In the 2001 U.S. bioterror attacks, 33,000 individuals required postexposure prophylaxis, 18 subjects contracted anthrax (11 inhalation, 7 cutaneous), and despite optimal medical therapy, 5 deaths resulted. Rapid protection against anthrax is required in a bioterrorism scenario; this study describes an in vivo gene transfer-based therapy that uses a human adenovirus (Ad)-based vector (AdαPAscAb) encoding a single-chain antibody directed against protective antigen (PA), a critical component of Bacillus anthracis lethal toxin. Following AdαPAscAb administration to mice, anti-PA single-chain antibody and anti-PA neutralizing activity were detected in serum over a 2-week period. Substantial survival advantage from anthrax lethal toxin was conferred by AdαPAscAb following administration from 1 to 14 days prior to toxin challenge, compared to no survival associated with an Ad vector expressing a control single-chain antibody. Passive immunotherapy with an Ad-based vector may be a rapid, convenient approach for protecting a susceptible population against anthrax, including use as an adjunct to antibiotic therapy.

AB - In the 2001 U.S. bioterror attacks, 33,000 individuals required postexposure prophylaxis, 18 subjects contracted anthrax (11 inhalation, 7 cutaneous), and despite optimal medical therapy, 5 deaths resulted. Rapid protection against anthrax is required in a bioterrorism scenario; this study describes an in vivo gene transfer-based therapy that uses a human adenovirus (Ad)-based vector (AdαPAscAb) encoding a single-chain antibody directed against protective antigen (PA), a critical component of Bacillus anthracis lethal toxin. Following AdαPAscAb administration to mice, anti-PA single-chain antibody and anti-PA neutralizing activity were detected in serum over a 2-week period. Substantial survival advantage from anthrax lethal toxin was conferred by AdαPAscAb following administration from 1 to 14 days prior to toxin challenge, compared to no survival associated with an Ad vector expressing a control single-chain antibody. Passive immunotherapy with an Ad-based vector may be a rapid, convenient approach for protecting a susceptible population against anthrax, including use as an adjunct to antibiotic therapy.

UR - http://www.scopus.com/inward/record.url?scp=12744269883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12744269883&partnerID=8YFLogxK

U2 - 10.1016/j.ymthe.2004.10.018

DO - 10.1016/j.ymthe.2004.10.018

M3 - Article

C2 - 15668135

AN - SCOPUS:12744269883

VL - 11

SP - 237

EP - 244

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 2

ER -